TipRanks
Advertisement
Advertisement

GB:0QAH Stock Latest News

Merck: Emerging Immunology Strength and HS Execution Support Unchanged $160 Price Target and Buy Rating
RatingsMerck: Emerging Immunology Strength and HS Execution Support Unchanged $160 Price Target and Buy Rating
22h ago
MRK
Spyre Therapeutics price target raised to $130 from $121 at Jones
PremiumThe Fly
Spyre Therapeutics price target raised to $130 from $121 at Jones
24h ago
MRK
SYRE
Merck Buy Rating Reiterated as Compelling Tulisokibart Data and Diversified Pipeline Support Outlook; $170 Price Target Maintained
PremiumRatings
Merck Buy Rating Reiterated as Compelling Tulisokibart Data and Diversified Pipeline Support Outlook; $170 Price Target Maintained
24h ago
MRK
Shattuck Labs has positive readthrough from Merck data, says H.C. Wainwright
PremiumThe Fly
Shattuck Labs has positive readthrough from Merck data, says H.C. Wainwright
2d ago
MRK
STTK
Merck says tulisokibart met primary, secondary endpoints in Phase 2b study
PremiumThe Fly
Merck says tulisokibart met primary, secondary endpoints in Phase 2b study
2d ago
MRK
Merck price target raised to $180 from $155 at Scotiabank
PremiumThe FlyMerck price target raised to $180 from $155 at Scotiabank
3d ago
MRK
Merck enters global license agreement with SciBrunch Therapeutics for SPR2015
Premium
The Fly
Merck enters global license agreement with SciBrunch Therapeutics for SPR2015
4d ago
MRK
Merck, Daiichi Sankyo voluntarily withdraw BLA for ifinatamab deruxtecan
Premium
The Fly
Merck, Daiichi Sankyo voluntarily withdraw BLA for ifinatamab deruxtecan
7d ago
MRK
Merck, Eisai announce FDA approval of Welireg plus Lenvima
PremiumThe Fly
Merck, Eisai announce FDA approval of Welireg plus Lenvima
7d ago
MRK
FDA approves Welireg and Lenvima combo for ccRCC
PremiumThe Fly
FDA approves Welireg and Lenvima combo for ccRCC
8d ago
MRK
Merck’s remigromig meets primary endpoint in Phase 2b/3 DME trial
PremiumThe Fly
Merck’s remigromig meets primary endpoint in Phase 2b/3 DME trial
8d ago
MRK
Merck: Catalyst-Rich Oncology and Immunology Pipeline Supports Buy Rating; $166 Price Target Reaffirmed
PremiumRatings
Merck: Catalyst-Rich Oncology and Immunology Pipeline Supports Buy Rating; $166 Price Target Reaffirmed
9d ago
MRK
Merck says FDA approves update for U.S. product label for Winrevair
PremiumThe FlyMerck says FDA approves update for U.S. product label for Winrevair
10d ago
MRK
Trump Trade: U.S. announces deal with Denmark over Greenland’s security
Premium
The Fly
Trump Trade: U.S. announces deal with Denmark over Greenland’s security
11d ago
AZN
BMY
Merck says Japan’s MHLW approves Keytruda Qlex
Premium
The Fly
Merck says Japan’s MHLW approves Keytruda Qlex
11d ago
MRK
U.S. weighs allowing most pharma licensing deals with China, Reuters says
PremiumThe Fly
U.S. weighs allowing most pharma licensing deals with China, Reuters says
14d ago
AZN
BMY
Merck says CHMP adopts positive opinion on Keytruda/Padcev combination
PremiumThe Fly
Merck says CHMP adopts positive opinion on Keytruda/Padcev combination
14d ago
MRK
Perspective Therapeutics announces trial collaboration agreement with Merck
PremiumThe Fly
Perspective Therapeutics announces trial collaboration agreement with Merck
18d ago
MRK
CATX
Merck price target raised to $172 from $150 at HSBC
PremiumThe Fly
Merck price target raised to $172 from $150 at HSBC
22d ago
MRK
Leerink ups Merck price target on pipeline momentum
PremiumThe FlyLeerink ups Merck price target on pipeline momentum
23d ago
MRK
Merck price target raised to $161 from $127 at Leerink
Premium
The Fly
Merck price target raised to $161 from $127 at Leerink
23d ago
MRK
Merck price target raised to $170 from $146 at Guggenheim
Premium
The Fly
Merck price target raised to $170 from $146 at Guggenheim
24d ago
MRK
MRNA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >